Pharmacokinetic-Pharmacodynamic Modeling of the Antitumor Effects of SGN-CD19A, a Novel Antibody-Drug Conjugate, in Mice

被引：0
|
作者：
Zhao, Baiteng [1 ]
Stevison, Faith [1 ]
Law, Che-Leung [2 ]
Han, Tae H. [1 ]
机构：
[1] Seattle Genet Inc, Clin Pharmacol, Bothell, WA 98021 USA
[2] Seattle Genet Inc, Preclin Res, Bothell, WA 98021 USA
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2013年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S17 / S18
页数：2
相关论文
共 50 条
  • [1] SGN-CD19A: A novel Anti-CD19 antibody drug conjugate
    Albertson, Tina M.
    Sandalic, Lali
    Zhao, Baiteng
    Kostic, Ana
    Law, Che-Leung
    CANCER RESEARCH, 2014, 74 (19)
  • [2] Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development
    Aman P. Singh
    Young G. Shin
    Dhaval K. Shah
    Pharmaceutical Research, 2015, 32 : 3508 - 3525
  • [3] Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development
    Singh, Aman P.
    Shin, Young G.
    Shah, Dhaval K.
    PHARMACEUTICAL RESEARCH, 2015, 32 (11) : 3508 - 3525
  • [4] Model-based alternative clinical trial designs and evaluations for SGN-CD19A, a novel antibody-drug conjugate
    Zhao, Baiteng
    Albertson, Tina M.
    Law, Che-Leung
    O'Meara, Megan M.
    Kostic, Ana
    Han, Tae H.
    CANCER RESEARCH, 2014, 74 (19)
  • [5] Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts
    Jones, Luke
    McCalmont, Hannah
    Evans, Kathryn
    Mayoh, Chelsea
    Kurmasheva, Raushan T.
    Billups, Catherine A.
    Houghton, Peter J.
    Smith, Malcolm A.
    Lock, Richard B.
    PEDIATRIC BLOOD & CANCER, 2019, 66 (08)
  • [6] Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma
    Moskowitz, Craig H.
    Forero-Torres, Andres
    Shah, Bijal D.
    Advani, Ranjana
    Hamlin, Paul
    Kim, Stella
    Kostic, Ana
    Sandalic, Larissa
    Zhao, Baiteng
    Fanale, Michelle A.
    BLOOD, 2014, 124 (21)
  • [7] Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Acute Leukemia and Highly Aggressive Lymphoma
    Fathi, Amir T.
    Chen, Robert
    Trippett, Tanya M.
    O'Brien, Maureen M.
    DeAngelo, Daniel J.
    Shah, Bijal D.
    Cooper, Todd M.
    Foran, James M.
    Hale, Gregory A.
    Pressey, Joseph
    Silverman, Lewis B.
    Tibes, Raoul
    Kim, Stella
    Albertson, Tina M.
    Sandalic, Larissa
    Zhao, Baiteng
    Borate, Uma
    BLOOD, 2014, 124 (21)
  • [8] A First-In-Human Phase 1 Study Of The Antibody-Drug Conjugate SGN-CD19A In Relapsed Or Refractory B-Lineage Acute Leukemia and Highly Aggressive Lymphoma
    Borate, Uma
    Fathi, Amir T.
    Shah, Bijal D.
    DeAngelo, Daniel J.
    Silverman, Lewis B.
    Cooper, Todd Michael
    Albertson, Tina M.
    O'Meara, Megan M.
    Sandalic, Larissa
    Stevison, Faith
    Chen, Robert
    BLOOD, 2013, 122 (21)
  • [9] SGN-35C: A Novel CD30-Directed Antibody-Drug Conjugate for the Treatment of Lymphomas
    Hamblett, Kevin J.
    Cochran, Julia
    Snead, Katie
    Jin, Steven
    Yumul, Roma
    Simmons, Jessica
    Stone, Ivan
    Lyski, Ryan
    Schrum, Jason P.
    Lim, Andrea R.
    Clarke, Astrid
    BLOOD, 2023, 142
  • [10] SGN-CD48A: a Novel Humanized Anti-CD48 Antibody-Drug Conjugate for the Treatment of Multiple Myeloma
    Lewis, Tim S.
    Olson, Devra
    Gordon, Kristine
    Sandall, Sharsti
    Quick, Marsha
    Finn, Margo
    Westendorf, Lori
    Linares, Germein
    Leiske, Chris
    Nesterova, Albina
    Huang, Lanshan
    Goswami, Maitrayee
    Wang, Sa
    Law, Che-Leung
    BLOOD, 2016, 128 (22)
12345